🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the battle against drug-resistant strains of the infection, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are escalating around the world, with figures suggesting in excess of 82 million new cases per year. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely development in the reality of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Health officials are increasingly worried about the increase in drug-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance found that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Clearance

One new antibiotic, alternatively called a brand name, was approved by the US Food and Drug Administration in mid-December for combating gonorrhoea. This infection can lead to major issues, including infertility. Scientists anticipate that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This medication, which is employed against urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This authorization marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Results and Worldwide Availability

According to findings published in a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which uses a dual-drug approach. The trial involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have voiced hope. Having a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is deemed vital to reduce the burden of the disease for patients and to prevent the spread of extremely resistant gonorrhoea around the world.